epirubicin / Generic mfg. - LARVOL DELTA

PD-1 Inhibitor Sintilimab Concurrent with Epirubicin, Cyclophosphamide, and Nab-Paclitaxel as Neoadjuvant Therapy for Triple-Negative Breast Cancer: A Single-Arm, Phase II Study (ESMO 2026) - No abstract available

Clinical • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Decentralised capillary therapeutic drug monitoring of epirubicin and taxanes in early breast cancer (ESMO 2026) - No abstract available

Breast Cancer • Oncology • Solid Tumor

Oncologic Outcomes and Prognostic Determinants Following Neoadjuvant Radiotherapy and Surgical Resection in Myxoid Liposarcoma (ASTRO 2026) - "Materials/ We retrospectively analyzed 52 consecutive patients with MLPS treated between 2002 and 2024 with preoperative RT (50 Gy in 25 fractions), with or without concurrent chemotherapy (epirubicin–ifosfamide), followed by surgical resection. Neoadjuvant RT, with or without chemotherapy, followed by surgery provides excellent local control and favorable long-term survival in patients with myxoid liposarcoma. High-grade disease remains the principal adverse prognostic factor, while incomplete resection compromises local control. Treatment-related toxicity is acceptable, supporting the safety and effectiveness of preoperative RT-based approaches in this radiosensitive sarcoma subtype."

Clinical • Liposarcoma • Oncology • Sarcoma • Solid Tumor

A Machine Learning Framework Enables Supervised Treatment Response Prediction from Tumor Transcriptomics across Cancer Types. (PubMed, Cancer Res) - "To address this, we assembled the largest transcriptomic resource for drug response prediction to date, spanning 91 cohorts, 5,675 patients, nine cancer types, and six frontline therapies: anti-PD-1/PD-L1 immune-checkpoint inhibitors, trastuzumab, bevacizumab, BRAF inhibitors, paclitaxel, and FAC/FEC (fluorouracil-adriamycin-cyclophosphamide/fluorouracil-epirubicin-cyclophosphamide) chemotherapy. Robustness analysis revealed that predictive performance plateaued for some therapies with increasing training cohorts but continued to improve for others. These findings suggest inherent limits of supervised brute-force learning for certain treatments, but additional data and deeper mechanistic modeling may further enhance transcriptomics-based predictors."

IO biomarker • Journal • Oncology

Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study. (PubMed, Adv Ther) - P3 | "Trastuzumab biosimilar EG12014 and ref-TRA have equivalent efficacy, and comparable safety, immunogenicity, and PK profiles, in patients with EBC. Clinical trial registration NCT03433313; EudraCT Number 2017-003973-33."

Journal • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Modified Newcastle Regimen Improves Survival Despite Central Nervous System Relapse in Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma. (PubMed, EJHaem) - "The Newcastle regimen, comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), ifosfamide, etoposide, and epirubicin (IVE), and intermediate-dose methotrexate for central nervous system (CNS) prophylaxis, has demonstrated promising outcomes in enteropathy-associated T-cell lymphoma (EATL) but has not been evaluated in MEITL, where the CNS relapse risk informing methotrexate use remains poorly characterized. The mNewcastle regimen may provide superior survival compared with CHOP-based chemotherapy in MEITL, while CNS relapse remains a clinical concern. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission."

Journal • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial. (PubMed, Signal Transduct Target Ther) - P2 | "In conclusion, neoadjuvant treatment of tislelizumab with nab-paclitaxel and anthracycline-based chemotherapy showed promising clinical activity and was well-tolerated among TNBC patients, without high incidence of TRAEs. These findings provide evidence supporting neoadjuvant tislelizumab with chemotherapy as an effective rational approach for treating TNBC."

Journal • P2 data • Alopecia • Breast Cancer • Hepatology • Immunology • Liver Failure • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • CDKN1A

Exploratory phase II trial of camrelizumab (an anti-PD-1 antibody) combined with apatinib (a VEGFR-2 inhibitor) and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis (SABCS 2025) - P2 | "The treatment regimen consisted of camrelizumab (200 mg intravenously every 2 weeks, 12 cycles), apatinib (250 mg orally daily), and alternating chemotherapy [nab-paclitaxel (d1, 8, 15 every 4 weeks) for 4 cycles and epirubicin plus cyclophosphamide (every 2 weeks) for 4 cycles]. From June 2023 to April 2024, 35 patients were enrolled, of whom 1 patient withdrew due to adverse reaction intolerance. In conclusion, camrelizumab and apatinib combined with chemotherapy have good clinical efficacy and good safety as neoadjuvant treatments for stage II-III TNBC, warranting further investigation and potential clinical application. This innovative dual-score system stratifies pretreatment prognosis (PRPscore) and dynamically evaluates therapeutic efficacy (EAscore), enabling precision neoadjuvant optimization."

Biomarker • Clinical • IO biomarker • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • CXCL1 • IL17A • IL18 • MMP7 • PD-L1 • TP53

Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial. (PubMed, JAMA) - P3 | "The chemotherapy included nab-paclitaxel (100 mg/m2) and carboplatin (area under the curve, 1.5) on days 1, 8, and 15 in 28-day cycles for the first 16 weeks followed by epirubicin (90 mg/m2) and cyclophosphamide (500 mg/m2) every 2 weeks for 8 weeks. Among patients with early or locally advanced triple-negative breast cancer, the addition of camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response. ClinicalTrials.gov Identifier: NCT04613674."

Clinical • Combination therapy • Journal • Metastases • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial. (SABCS 2024) - P3 | " Patients with previously untreated, invasive stage II (T2N0-1M0/T3N0M0) or III (T2N2-3M0/T3N1-3M0) TNBC were randomized (1:1) to receive neoadjuvant camrelizumab (200 mg, Q2W) or placebo plus chemo (nab-paclitaxel [100 mg/m2, D1, D8, D15, Q4W] + carboplatin [AUC 1.5, D1, D8, D15, Q4W] for 16 weeks, followed by dose-dense epirubicin [90 mg/m2, Q2W] + cyclophosphamide [500 mg/m2, Q2W] for 8 weeks). Addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy significantly improved pCR rate in early or locally advanced TNBC, with a manageable safety profile. Early survival data also favored the camrelizumab + chemo group."

Clinical • IO biomarker • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • NODAL

PET micro/nanoplastic exposure alters the physicochemical fingerprint of epirubicin-albumin mixtures and modulates bacterial growth and stress responses in Escherichia coli and Staphylococcus aureus. (PubMed, RSC Adv) - "However, free EPI was not independently quantified, and contributions from filter-passing PET species or leachable constituents could not be excluded. The findings therefore do not establish binding stoichiometry, thermodynamic affinity, competitive displacement, or redistribution of EPI among aqueous, albumin-associated, and particle-associated fractions."

Journal

Simultaneous Occurrence of Breast Cancer Metastases and Cervical Cancer Metastases in the Same Lymph Node. (PubMed, Case Rep Obstet Gynecol) - "Following the recommendation of our interdisciplinary tumor conference, we began treatment with neoadjuvant chemotherapy in reverse order, with four cycles of carboplatin/Taxol (corresponding to first-line chemotherapy for cervical cancer), followed by four cycles of EC (epirubicin and cyclophosphamide) (corresponding to first-line chemotherapy for breast cancer), mammoplasty, and adjuvant radiotherapy, including internal mammary and supraclavicular node irradiation. A combination of systemic therapy, radiotherapy, and surgery may achieve complete remission in selected patients, as we saw in our case. Mortality rates remain unclear due to the limited number of reported cases."

Journal • Breast Cancer • Cervical Cancer • Oncology • Solid Tumor

TACE combined with apatinib versus TACE alone for unresectable hepatocellular carcinoma in China: a cost-effectiveness and budget impact analysis. (PubMed, BMJ Open) - P4 | "The TACE-apatinib regimen provides clear clinical benefit for uHCC in China, but its cost-effectiveness and budget feasibility are contingent on drug price. Successful national centralised procurement is the key policy lever to enable value-based access, as demonstrated by this integrated evidence framework."

Clinical • HEOR • Journal • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial. (PubMed, Nat Med) - P3 | "We conducted a double-blind, placebo-controlled phase 3 study (KEYNOTE-756) in which patients with previously untreated ER+/HER2- grade 3 high-risk invasive breast cancer (T1c-2 (≥2 cm), cN1-2 or T3-4, cN0-2) were randomly assigned (1:1) to neoadjuvant pembrolizumab 200 mg or placebo Q3W given with paclitaxel QW for 12 weeks, followed by four cycles of doxorubicin or epirubicin plus cyclophosphamide Q2W or Q3W. Follow-up continues for event-free survival. ClinicalTrials.gov identifier: NCT03725059 ."

Journal • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2

Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC) (ESMO 2024) - P2 | "Neo-CheckRay (NCT03875573) is the first prospective, international, phase 2, randomized trial investigating this treatment. Eligible patients (pts) with newly diagnosed cT1c-3 (≥ 2 cm) cN0 or cT1c-3 (≥ 1.5 cm) cN1-3, grade 2 (Ki67 ≥ 15%) or grade 3, MammaPrint (MP) high risk, invasive ER+/HER2- BC were randomized 1:1:1 to arm 1: neo-adjuvant paclitaxel q1w x12 with SBRT at week 5 (3x8 Gy targeting the primary tumour, avoiding lymph nodes and normal breast tissue), followed by dose-dense epirubicin/cyclophosphamide q2w x4; arm 2: arm 1 + durva 1500mg q4w x5; and arm 3: arm 2 + ole 3000 mg q2w x4 then q4w x3. The addition of durva+/- ole numerically increases pCR and RCB 0/1 rates compared to NACT+SBRT. Final statistical analysis will be presented at the conference. Ongoing translational research will shed light on the mechanisms of response."

Clinical • Late-breaking abstract • P2 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Cutaneous Angiosarcoma: A Case Highlighting the Dismal Prognosis of an Aggressive Malignancy (SOHO 2026) - "In advanced stages, immune checkpoint inhibitors such as pembrolizumab, nivolumab, and ipilimumab, as well as targeted therapies including pazopanib and sorafenib, have shown promising clinical responses and survival benefits...In the absence of immunotherapy and targeted agents in Venezuela, treatment was limited to epirubicin, ifosfamide, and mesna... This case highlights the fulminant course and devastating prognosis of unresectable cutaneous angiosarcoma while emphasizing the therapeutic limitations faced in resource-constrained settings. CD: cluster of differentiation, FLI-1: Friend leukemia integration 1 transcription factor."

Clinical • IO biomarker • Angiosarcoma • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Non-melanoma Skin Cancer • Oncology • Sarcoma • Solid Tumor • CD31 • FLI1 • PECAM1

Cardiovascular and Survival Outcomes Among Adults With Hematologic Malignancies Receiving Anthracyclines With vs Without Dexrazoxane: A Real-World Propensity-Matched Analysis (SOHO 2026) - "Patients: Adults aged 18–75 years with a hematologic malignancy (ALL; AML; CLL; CML; Hodgkin lymphoma; DLBCL; follicular, mantle cell, or mature T/NK lymphoma; multiple myeloma; MDS; polycythemia vera) diagnosed on/after January 1, 2010, initiating an anthracycline (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone) within 3 months of diagnosis, with (n = 1887) or without (n = 40607) concurrent dexrazoxane. Dexrazoxane was paradoxically associated with higher cardiomyopathy, heart failure, MACE, and mortality, contrary to randomized cardioprotection trials. These results almost certainly reflect channeling bias: dexrazoxane is preferentially given to patients receiving high cumulative anthracycline doses or with preexisting/emerging cardiotoxicity, which are not captured by administrative coding. ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, CLL: chronic lymphocytic leukemia, CML: chronic myeloid leukemia, DLBCL: diffuse large B-cell..."

Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Polycythemia Vera

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study (SABCS 2023) - P3 | "Here, we present updated EFS results after a median follow-up of ~5 y. Eligible pts with previously untreated, non-metastatic, centrally confirmed TNBC (stage T1c N1-2 or T2-4 N0-2 per American Joint Committee on Cancer) were randomized 2:1 to neoadjuvant pembro 200 mg Q3W or placebo (pbo), both given with 4 cycles of paclitaxel + carboplatin, then with 4 cycles of doxorubicin or epirubicin + cyclophosphamide. Neoadjuvant pembro + chemo followed by adjuvant pembro continues to show a clinically meaningful improvement in EFS compared with neoadjuvant chemo alone in pts with early-stage TNBC. This is seen across subgroups and regardless of the pCR outcome. Table."

Clinical • IO biomarker • Late-breaking abstract • P3 data • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • NODAL • PD-L1

Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: The Second Hospital of Anhui Medical University

New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC). (SABCS 2024) - P2 | "Pts were randomized 2:2:1 to: (A) HER3-DXd 5.6 mg/kg every (Q) 21 days (D) for 6 cycles; (B) HER3-DXd plus QD LET (+/- LHRH agonist); (C) CT with 4 cycles of EC/AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 Q14 or 21 D) followed by weekly paclitaxel 80mg/m2 for 12 weeks. In SOLTI VALENTINE, treatment with HER3-DXd, with or without LET, resulted in similar pCR rates to CT, while exhibiting a lower incidence of grade ≥3 TEAEs. CelTIL score at C2D1 correlated with response to HER3-DXd, but not to CT. The ongoing translational analysis, as well as the survival outcomes of VALENTINE, will provide further insights into the activity of HER3-DXd in EBC and clarify its potential role as a treatment strategy for high-risk HR+/HER2-neg breast cancer."

Clinical • Combination therapy • Late-breaking abstract • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ERBB3 • HER-2

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. (PubMed, Ann Oncol) - P2/3 | "In high-risk HR+/HER2- EBC, neoadjuvant nab-paclitaxel q1w appears superior to sb-paclitaxel q2w regarding pCR. Combining RS and ET-response assessment appears to select patients with highest pCR rates. The disadvantage of higher RS for dDFS is reduced in patients with pCR. These are the first results from a large neoadjuvant randomized trial supporting the use of RS to help select patients for neoadjuvant chemotherapy in high-risk HR+/HER2- EBC."

Journal • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52 / ATHENE) (ESMO-BC 2023) - "Outcome according to PD-L1 expression status is currently analyzed and will also be presented at the meeting. Conclusions For HER2-positive EBC, a neoadjuvant chemotherapy de-escalation immunotherapy regimen with trastuzumab, pertuzumab, atezolizumab and epirubicin is highly effective and safe and merits further investigation."

Clinical • Combination therapy • IO biomarker • P2 data • Breast Cancer • Cardiovascular • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PD-L1

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. (PubMed, Lancet Oncol) - P3 | "Updated results from the GIM2 study support that optimal adjuvant chemotherapy for patients with high-risk early breast cancer should not include fluorouracil and should use a dose-dense schedule."

Journal • P3 data • Alopecia • Breast Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor

Role of neoadjuvant versus adjuvant chemotherapy, dose density, and treatment schedule in biologically high-risk HR+/HER2- breast cancer: A pooled analysis of the WSG ADAPT-HR+/HER2- and PlanB trials. (ASCO 2026) - P2/3, P3 | "In ADAPT-HR+/HER2-, pts at high-risk received 8× weekly nab-paclitaxel vs. 4× biweekly sb-paclitaxel, followed by epirubicin + cyclophosphamide (EC) in either the neoadjuvant or adjuvant setting. Our exploratory retrospective analysis does not show a significant survival difference by anthracycline use or treatment setting (neoadjuvant vs adjuvant) in high-risk HR+/HER2- eBC pts who are candidates for CTx. Optimal use of dose-dense CTx in the context of docetaxel-based treatment requires further investigation."

Late-breaking abstract • Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov) - P3 | N=194 | Recruiting | Sponsor: Hamlet Pharma AB | Not yet recruiting ➔ Recruiting

Enrollment open • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor